Are Designer Babies Becoming Real? The Truth About CRISPR- For decades, the designer baby existed purely in the realm of science fiction — a cautionary symbol in dystopian novels, a provocative thought experiment in bioethics seminars, and a recurring villain in films about humanity overreaching its limits. Then, in November 2018, a Chinese scientist named He Jiankui announced to the world that he had already done it. Twin girls, Lulu and Nana, had been born with edited genomes. The scientific community erupted. Governments scrambled. And suddenly, the question was no longer whether human genetic engineering was theoretically possible. It was about how far it had already gone, and where it was heading next.
The tool at the centre of this story is CRISPR-Cas9 — and understanding what it actually is, what it can and cannot do, separates informed conversation from science fiction dressed up as fact.
What CRISPR Actually Is
CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats — a mouthful that refers to sequences in bacterial DNA that scientists recognised as part of a natural immune system. Bacteria use these sequences, along with an associated protein called Cas9, to identify and cut the DNA of invading viruses. Researchers Jennifer Doudna and Emmanuelle Charpentier, who shared the Nobel Prize in Chemistry in 2020 for their work, realised this mechanism could be repurposed as a precise molecular tool for editing DNA in any organism.
The way it works is conceptually elegant. A short piece of synthetic RNA is designed to match a specific DNA sequence in a genome. This guide RNA escorts the Cas9 protein to the exact target location, where Cas9 acts like a pair of molecular scissors, cutting both strands of the DNA double helix. The cell’s own repair machinery then kicks in — and researchers can exploit this repair process to either disable a gene or insert a new one in its place.
What made CRISPR revolutionary compared to earlier gene-editing approaches was its speed, accessibility, and relative precision. Techniques that once took years and enormous resources could now be performed in weeks at a fraction of the cost. Laboratories around the world adopted it almost immediately.
He Jiankui and the Line That Was Crossed
Most CRISPR research involves somatic cells — the ordinary cells of a living body, like blood cells or liver cells. Changes made to somatic cells affect only the individual being treated and do not pass to future generations. This is the basis of most current gene therapy, and the scientific and ethical consensus around it, while still evolving, is broadly supportive for treating serious diseases.
He Jiankui crossed a fundamentally different line. He edited germline cells — embryos — meaning the changes he made were heritable. If Lulu and Nana have children, those children will carry the edit too. And the edit itself was not correcting a deadly inherited disease. He targeted a gene called CCR5, which encodes a protein that HIV uses to enter cells, attempting to confer resistance to HIV infection. Critics were swift and blunt: this was not a therapeutic necessity. It was enhancement of healthy embryos for a condition they did not have and might never encounter — performed outside any regulatory framework, without adequate informed consent from the parents, and with significant unresolved safety concerns.
He Jiankui was sentenced to three years in prison by a Chinese court in 2019. But the genie, as many scientists noted uneasily, was out of the bottle.
What CRISPR Can Realistically Do Right Now
Despite the alarm, it is worth being precise about the current state of the technology — because breathless headlines often blur the line between what CRISPR has achieved, what it might achieve, and what remains deeply uncertain.
In medicine, CRISPR-based therapies are producing genuine breakthroughs. In late 2023, the United States and United Kingdom approved the first CRISPR-based treatment for sickle cell disease — a painful, life-limiting inherited condition caused by a single gene mutation. The therapy, called Casgevy, edits patients’ own blood stem cells to reactivate foetal haemoglobin production, effectively compensating for the defective gene. Early results have been transformative for patients who previously had few options. Similar approaches are being developed for beta-thalassemia, certain cancers, and inherited blindness conditions.
These are somatic therapies: they treat individuals, they do not alter the human germline, and they represent a medically and ethically defensible use of the technology. The scientific community broadly supports this direction.
Germline editing — the kind He Jiankui performed — remains a different matter entirely. It is banned or subject to moratoriums in most countries. The technical challenges alone are significant: CRISPR is not perfectly precise. Off-target edits, where the molecular scissors cut DNA at unintended locations, remain a real concern. Mosaicism — where only some cells in an embryo carry the intended edit — complicates outcomes further. In a living adult, an off-target effect is serious but contained. In a germline edit, it is heritable.
The Designer Baby Question
So are designer babies — children selected or engineered for traits like intelligence, athleticism, or appearance — becoming real?
Scientifically, the honest answer is: not in any meaningful sense, and not any time soon. The gap between editing a single gene to prevent a known, devastating disease and engineering complex polygenic traits is enormous. Most of the characteristics people associate with designer babies — intelligence, height, personality, athletic ability — are influenced by thousands of genetic variants interacting with each other and with environmental factors in ways that are not remotely understood well enough to engineer. Editing one gene does not produce a smarter or faster child. The biology is irreducibly complex.
What is closer to reality, and already practised, is preimplantation genetic diagnosis (PGD) — the screening of IVF embryos for known genetic diseases before implantation. This is not editing; it is selection. And it already raises ethical questions about which lives are considered worth preventing. As genetic screening becomes more sophisticated, the boundaries between treatment, prevention, and enhancement will become increasingly difficult to police.
The deeper concern among bioethicists is not that someone will engineer a supervillain or a genius in a lab next year. It is that incremental steps — each individually defensible — accumulate into something society never explicitly chose. Treating a fatal disease. Preventing a serious disability. Reducing susceptibility to illness. Optimising development. The line between medicine and enhancement does not announce itself.
Real Enough to Take Seriously
CRISPR is not science fiction. It is an active, rapidly advancing technology that is already changing medicine and will continue to do so. The designer baby, in the Hollywood sense of a child engineered to order, remains far beyond current capabilities and faces scientific barriers that are not about to collapse overnight.
But He Jiankui proved that the ethical barriers can be bypassed by a single rogue actor with access to the tools. That is the real lesson of 2018 — not that designer babies are here, but that the governance of this technology matters enormously, and that the conversation between scientists, ethicists, governments, and the public cannot afford to lag behind the pace of the science.
The future of human genetics will not be written by fiction. It will be written by the choices made in laboratories, courtrooms, and policy chambers right now.
History’s Greatest Conspiracies That Actually Happened | Maya
